Tuesday Aug 26
Cubist to Present New Data from Antibiotics Portfolio at 54th...
Cubist Pharmaceuticals, Inc. today announced that it will present new data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy , September 5-9 in Washington, D.C. Data highlighted will offer insights into Cubist's commitment to identifying treatments for drug-resistant Gram-positive and Gram-negative bacteria that cause ... (more)
Mon Aug 25, 2014
Cubist to Present at Morgan Stanley Global Healthcare Conference
The presentation will be held at the Grand Hyatt New York hotel in New York City on Monday, September 8, 2014 at 10:30 a.m. Eastern Time.
Press release distribution, EDGAR filing, XBRL, regulatory filings
A live webcast and replay will be a... )--Research and Markets has announced the addition of the "MIMO-based Communications Systems Technologies, Market... )--Artisan announced the availability of in-app messaging capabilities, which are integrated into its Mobile Experience Management platform for mobile app analytics, per... )--Accenture was ... (more)
Fri Aug 22, 2014
Customer Interaction Solutions
Allergan Receives Written Requests from Pershing Square; Cubist...
We are pleased to receive MAA acceptance for ceftolozane/tazobactam and look forward to working with the EMA on this important review," said Steven Gilman, Ph.D., Executive Vice President of Research and Development and Chief Scientific Officer of Cubist.
Cubist Pharmaceuticals, Inc. Announces EMA Acceptance Of...
Cubist Pharmaceuticals, Inc. today announced that the European Medicines Agency has accepted for review the Company's Marketing Authorization Application for its investigational antibiotic ceftolozane/tazobactam.
Wed Aug 20, 2014
The Double Whammy: Cubist's Recent FCPA Disclosure
In the FCPA enforcement world, corporate disclosures of potential violations carrying significant messages.
Cubist Pharmaceuticals Director Nancy J. Hutson Sells 9,000 Shares
Cubist Pharmaceuticals Director Nancy J. Hutson sold 9,000 shares of the stock in a transaction dated Monday, August 18th.
Insider Selling: Cubist Pharmaceuticals COO Unloads 1,003 Shares of Stock
Cubist Pharmaceuticals COO Robert J. Perez sold 1,003 shares of Cubist Pharmaceuticals stock on the open market in a transaction that occurred on Monday, August 18th.
DISCLAIMER: M.P., J.S., N.D., and A.R. are employed by Bouve College of Health Sciences as postdoctoral fellows with Cubist Pharmaceuticals, Inc. ABSTRACT: Vancomycin-resistant Enterococcus is a major cause of hospital-acquired infections in the United States.
Mon Aug 18, 2014
Cubist Pharmaceuticals Director Sells $585,000 in Stock
Cubist Pharmaceuticals Director Nancy J. Hutson unloaded 9,000 shares of the company's stock in a transaction dated Monday, August 18th.
Cubist Pharmaceuticals COO Unloads $63,871 in Stock
Cubist Pharmaceuticals COO Robert J. Perez unloaded 1,003 shares of the stock in a transaction that occurred on Monday, August 18th.
Cubist Pharmaceuticals Stock Rating Lowered by Zacks
They currently have a $58.00 price target on the stock. Zacks 's price objective points to a potential downside of 8.50% from the stock's previous close.
Cubist Pharmaceuticals, Inc. Could Be An Acquisition Target For Needy Pfizer Inc.
The timing may be right for a takeover of Cubist Pharmaceuticals Inc. The rising threat from drug-resistant germs and increasing calls from global health groups for more potent antibiotics is placing a premium on companies such as Cubist.
Thu Aug 14, 2014
Did The Medicines Company Trump Cellceutix And Others In A $1B-Plus Skin Infection Market?
Cellceutix's Brilacidin flagship one step antibiotic potentially simplifies patient results with a single dose possibly making Brilacidin the physician's first choice for fighting skin infections and oral mucositis.
Mon Aug 11, 2014
Cubist Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall Of...
Cubist Pharmaceuticals, Inc. today announced it is voluntarily recalling nine lots of CUBICINA to the user level following complaints of foreign particulate matter in reconstituted vials.
CMO issues persist as Cubist announces third recall for potential glass in antibiotic
For the third time since last August, Cubist Pharmaceuticals has recalled lots of its antibiotic Cubicin injection due to the potential of glass particulates in a manufacturing line produced by an unnamed CMO .
Fri Aug 08, 2014
Cubist Pharmaceuticals Recalls CUBICIN
FDA is reporting that Cubist Pharmaceuticals has announced it is voluntarily recalling certain lots of CUBICIN to the user level due to the potential presence of glass particulate matter in vials produced by a contract manufacturer.
Thu Aug 07, 2014
FDA Approves Orbactiv (Oritavancin) for Skin Infections
The FDA has approved Orbactiv for injection for the treatment of adults with acute bacterial skin and skin-structure infections caused by susceptible designated Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus .
Wed Aug 06, 2014
Cubist Pharmaceuticals Issues Voluntary U.S. Recall of Certain Lots of CUBICIN
Cubist Pharmaceuticals today announced it is voluntarily recalling certain lots of CUBICINA to the user level due to the potential presence of glass particulate matter in vials produced by a contract manufacturer.
Cubist Pharmaceuticals Issues Voluntary U.S. Recall of Certain Lots...
Cubist Pharmaceuticals, Inc. today announced it is voluntarily recalling certain lots of CUBICIN to the user level due to the potential presence of glass particulate matter in vials produced by a contract manufacturer.